Faster Clinical Trials Test Pharma’s Supply Chains
The FDA is moving to accelerate early-stage drug development. Under Operation TrialBlazer, it aims to shorten the path to first-in-human studies, potentially putting more pressure on the supply operations supporting them.
Investigational medicines still need to be manufactured, packaged, labelled and delivered when patients are ready. Biologics, advanced therapies, global studies and direct-to-patient models are making that harder.
Visiongain values the global clinical trial supply and logistics market for pharma at US$7.92bn in 2026, rising to US$18.22bn by 2036 at a CAGR of 8.7%.
This week, we look at how faster development could change clinical supply, where providers are investing and what sponsors will need from their supply partners.
Visiongain Top Takeaways
- Faster development could move the bottleneck: If regulatory timelines shorten, delays in packaging, release and site supply will become harder to absorb.
- Just-in-time changes the inventory equation: Later packaging and labelling can reduce overproduction and expiry, but leave less room for weak forecasting or distribution delays.
- Advanced therapies raise the cost of failure: High-value biologics and cell and gene therapies put greater weight on cold-chain control, monitoring and contingency planning.
- Direct-to-patient adds another layer of execution: Hybrid trials bring patient-level scheduling, temperature control, returns and delivery visibility into the supply model.
- Regional networks trade distance for control: Local depots can shorten lead times and reduce cross-border exposure, but sponsors still need visibility across the wider trial network.
Faster IND Timelines Put Trial Readiness Under Pressure
Operation TrialBlazer is intended to shorten the path into first-in-human studies through measures including a proposed expedited IND pilot built around rolling submissions, alongside clearer Phase I CMC requirements.
The FDA says focusing on phase-appropriate Chemistry, Manufacturing and Controls requirements could save companies six to 12 months of development time. Regulatory review, however, is only one part of trial start-up. Sites, patient recruitment and investigational product must also be ready.
Recruitment can vary sharply between countries, while protocol changes can alter patient numbers or dosing after product has been manufactured and packaged. If sponsors have less time between regulatory preparation and study activation, forecasting errors become harder to absorb.
The opportunity is less about moving product faster than giving sponsors more flexibility over when and where clinical inventory is committed.
Just-in-Time Changes the Inventory Equation
Traditional clinical supply models often require investigational product to be packaged before actual demand is clear. That protects against shortages, but can leave sponsors with excess stock when recruitment slows, protocols change or products expire.
Almac Clinical Services’ Almac Adapt service uses just-in-time manufacturing to postpone final packaging and labelling until patient or site demand is clearer, giving sponsors more flexibility over clinical inventory.
The model reduces the amount of finished stock committed before enrolment is known, but puts more weight on forecasting and execution. Packaging capacity, release and distribution all need to respond quickly when demand changes.
The value lies less in carrying less stock than in giving sponsors more time to decide where that stock is needed.
Advanced Therapies Raise the Cost of Failure
Biologics and cell and gene therapies are raising the demands on clinical logistics. Products may require refrigerated, frozen or cryogenic handling, while small batches, limited stability windows and patient-specific treatments leave less room to recover from disruption.
DHL expanded its pharmaceutical airfreight cold-chain network in February 2026 as part of a €2bn investment in life sciences and healthcare logistics. Its network now connects more than 30 GDP-compliant hubs, including a dedicated Brussels-Cincinnati route for high-value biologics and time-critical cell and gene therapies.
The challenge extends beyond temperature control. Advanced therapies can require continuous monitoring, contingency planning and, in patient-specific treatments, an unbroken chain of identity and custody.
A failed shipment can affect more than logistics costs. When product is scarce or made for an individual patient, delays can disrupt the treatment schedule and the trial itself.
Direct-to-Patient Trials Shift the Logistics Burden
Hybrid trials are moving more trial activity away from research sites and into patients’ homes.
Direct-to-patient delivery requires tighter control over scheduling, temperature, patient privacy, proof of delivery and returns, often around individual dosing windows.
World Courier’s July 2026 guidance highlights the need to coordinate deliveries with patient availability and, where required, home nursing visits while maintaining temperature control and shipment visibility.
The model can reduce travel and widen access, particularly for geographically dispersed patients. It will not suit every study. Treatments requiring complex administration, intensive monitoring or poorly characterised safety profiles may still need to remain site-based.
The opportunity is not to move every trial activity into the home, but to identify where decentralisation genuinely improves access without increasing execution risk.
Regional Networks Put Inventory Closer to Demand
Multinational trials expose sponsors to different import rules, customs procedures, labelling requirements and storage standards. Recruitment may also move at very different rates from one market to another.
Tariff uncertainty and geopolitical disruption add another reason to reduce unnecessary cross-border movements and qualify alternative routes.
Marken expanded its Asia-Pacific clinical and commercial logistics offering in August 2026, supported by three GMP and GDP-compliant facilities in Singapore and more than 300,000 sq ft of additional storage capacity across its network.
Regional depots can shorten delivery routes and reduce repeated cross-border shipments, but their greater value is flexibility. Inventory can be positioned closer to active sites and reallocated as enrolment changes.
A global network matters less than how effectively sponsors can see and move stock within it. Product held in the wrong market offers little protection against a shortage elsewhere.
Market Outlook: Clinical Supply Moves Closer to Speed-to-Market
Efforts to shorten clinical development timelines will put greater weight on what happens after a study is cleared to proceed. Product still has to be available where recruitment is taking place without forcing sponsors to carry excessive inventory across every site and market.
Manufacturing, packaging and logistics remain essential, but forecasting, inventory visibility and the ability to redirect supply as enrolment changes are becoming just as important.
Providers with large networks will retain an advantage, particularly in cold chain and global distribution. Scale alone does not solve the problem if stock is committed too early or positioned in the wrong market.
Visiongain Insight: The competitive edge is shifting from capacity alone to control over inventory. Providers that can help sponsors delay allocation decisions, see demand earlier and move product before shortages emerge will be better placed as development timelines tighten.
From Visiongain
Visiongain’s healthcare, pharma and biotech reports help organisations assess where clinical development demand is growing, which capabilities are becoming more valuable and how trial models are changing across the pharmaceutical value chain.
The following reports examine markets where supply resilience, patient access and more flexible trial execution are becoming increasingly important to commercial performance:
- Clinical Trial Supply and Logistics for Pharma Market Report 2026-2036
- Decentralised Clinical Trials Market Report 2026-2036
- Women’s Clinical Trials & CROs Market Report 2026-2036
- Cell & Gene Therapy Cold Chain Logistics Market Report 2025-2035
